UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

In Vitro Evaluation of the Potential for Drug Interactions by Salidroside

Nutrients, 2023-08, Vol.15 (17), p.3723

2023

Volltextzugriff (PDF)

Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes

Drug metabolism and disposition, 2010-09, Vol.38 (9), p.1605-1611

2010

Volltextzugriff (PDF)

A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro

Drug metabolism and disposition, 2008-08, Vol.36 (8), p.1698-1708

2008

Volltextzugriff (PDF)

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction

Drug metabolism and disposition, 2009-08, Vol.37 (8), p.1658-1666

2009

Volltextzugriff (PDF)

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

Drug metabolism and disposition, 2017-10, Vol.45 (10), p.1049-1059

2017

Volltextzugriff (PDF)

Evaluation of models for predicting drug-drug interactions due to induction

Expert opinion on drug metabolism & toxicology, 2010-11, Vol.6 (11), p.1399-1416

2010

Volltextzugriff (PDF)

Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism

Journal of clinical pharmacology, 2011-02, Vol.51 (2), p.229-236

2011

Volltextzugriff (PDF)

Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group-An Industry Perspective

Drug metabolism and disposition, 2016-10, Vol.44 (10), p.1720-1730

2016

Volltextzugriff (PDF)

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome

Drug metabolism and disposition, 2017-05, Vol.45 (5), p.501-511

2017

Volltextzugriff (PDF)

Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin

Drug metabolism and disposition, 2013-05, Vol.41 (5), p.966-974

2013

Volltextzugriff (PDF)

Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper

Drug metabolism and disposition, 2013-09, Vol.41 (9), p.1598-1609

2013

Volltextzugriff (PDF)

Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction

Drug metabolism and disposition, 2006-10, Vol.34 (10), p.1742-1748

2006

Volltextzugriff (PDF)

Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions

Drug metabolism and pharmacokinetics, 2017-01, Vol.32 (1), p.S18-S18

Fahmi, Odette A.

2017

Volltextzugriff (PDF)

Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes

Drug metabolism and disposition, 2008-09, Vol.36 (9), p.1971-1974

2008

Volltextzugriff (PDF)

An exposure-response analysis based on rifampin suggests CYP3A4 induction is driven by AUC: an in vitro investigation

Xenobiotica, 2017-08, Vol.47 (8), p.673-681

2017

Volltextzugriff (PDF)

Lack of effect of tofacitinib (CP‐690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data

British journal of clinical pharmacology, 2012-07, Vol.74 (1), p.109-115

2012

Volltextzugriff (PDF)

Animal Models for Evaluation of Drug-Drug Interaction Potential of Biotherapeutics

Current drug metabolism, 2012-09, Vol.13 (7), p.947-950

2012

Volltextzugriff (PDF)

Utility of DPX2 cells for predicting CYP3A induction-mediated drug-drug interactions and associated structure-activity relationships

Drug metabolism and disposition, 2012-11, Vol.40 (11), p.2204-2211

2012

Volltextzugriff (PDF)

Application of CYP3A4 in vitro data to predict clinical drug–drug interactions; predictions of compounds as objects of interaction

British journal of clinical pharmacology, 2008-05, Vol.65 (5), p.680-692

2008

Volltextzugriff (PDF)

How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential

Drug metabolism and disposition, 2011-10, Vol.39 (10), p.1779

2011

Volltextzugriff (PDF)

A novel method using confocal laser scanning microscopy for sensitive measurement of P-glycoprotein-mediated transport activity in Caco-2 cells

Journal of pharmacy and pharmacology, 2011-08, Vol.63 (8), p.1015-1021

2011

Volltextzugriff (PDF)

Development of an in vitro drug–drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds

Journal of pharmacological and toxicological methods, 2008-11, Vol.58 (3), p.206-214

2008

Volltextzugriff (PDF)

IIn Vitro/I Evaluation of the Potential for Drug Interactions by Salidroside

Nutrients, 2023-08, Vol.15 (17)

2023

Volltextzugriff (PDF)

The time to move cytochrome p450 induction into mainstream pharmacology is long overdue

Drug metabolism and disposition, 2007-04, Vol.35 (4), p.697-698

2007

Volltextzugriff (PDF)

Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6

Drug metabolism and disposition, 2003-05, Vol.31 (5), p.596-605

2003

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(10)

Publikationsform

Artikel
(26)
Dissertationen
(1)

Sprache

Englisch
(27)
Japanisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

In Vitro Evaluation of the Potential for Drug Interactions by Salidroside

Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes

A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

Evaluation of models for predicting drug-drug interactions due to induction

Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism

Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group-An Industry Perspective

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome

Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin

Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper

Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction

Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions

Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes

An exposure-response analysis based on rifampin suggests CYP3A4 induction is driven by AUC: an in vitro investigation

Lack of effect of tofacitinib (CP‐690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data

Animal Models for Evaluation of Drug-Drug Interaction Potential of Biotherapeutics

Utility of DPX2 cells for predicting CYP3A induction-mediated drug-drug interactions and associated structure-activity relationships

Application of CYP3A4 in vitro data to predict clinical drug–drug interactions; predictions of compounds as objects of interaction

How current understanding of clearance mechanisms and pharmacodynamics of therapeutic proteins can be applied for evaluation of their drug-drug interaction potential

A novel method using confocal laser scanning microscopy for sensitive measurement of P-glycoprotein-mediated transport activity in Caco-2 cells

Development of an in vitro drug–drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds

IIn Vitro/I Evaluation of the Potential for Drug Interactions by Salidroside

The time to move cytochrome p450 induction into mainstream pharmacology is long overdue

Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6

Suchergebnisse filtern